Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Operating Leases: 2022-2025

Historic Operating Leases for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to $4.6 million.

  • Gossamer Bio's Operating Leases fell 27.16% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 27.16%. This contributed to the annual value of $4.4 million for FY2024, which is 2954.17% up from last year.
  • As of Q3 2025, Gossamer Bio's Operating Leases stood at $4.6 million, which was down 4.25% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Operating Leases ranged from a high of $8.5 million in Q1 2022 and a low of $144,000 during Q4 2023.
  • In the last 3 years, Gossamer Bio's Operating Leases had a median value of $4.6 million in 2025 and averaged $4.1 million.
  • Its Operating Leases has fluctuated over the past 5 years, first slumped by 95.82% in 2023, then skyrocketed by 2,954.17% in 2024.
  • Gossamer Bio's Operating Leases (Quarterly) stood at $3.4 million in 2022, then slumped by 95.82% to $144,000 in 2023, then skyrocketed by 2,954.17% to $4.4 million in 2024, then fell by 27.16% to $4.6 million in 2025.
  • Its Operating Leases stands at $4.6 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.0 million for Q1 2025.